Which has stronger earnings and valuation, LNTH or PRGO?

Lantheus has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.56B 4.19 $233.56M $4.14 24.15 Perrigo $4.25B 0.46 -$1.43B -$12.51 N/A

Is LNTH or PRGO more profitable?

Lantheus has a net margin of 17.69% compared to Perrigo's net margin of -41.85%. Lantheus' return on equity of 28.10% beat Perrigo's return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 17.69% 28.10% 14.35% Perrigo -41.85% 11.25% 4.08%

Does the media favor LNTH or PRGO?

In the previous week, Lantheus had 6 more articles in the media than Perrigo. MarketBeat recorded 11 mentions for Lantheus and 5 mentions for Perrigo. Lantheus' average media sentiment score of 1.26 beat Perrigo's score of 0.58 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Perrigo 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Is PRGO or BLTE more profitable?

Belite Bio has a net margin of 0.00% compared to Perrigo's net margin of -41.85%. Perrigo's return on equity of 11.25% beat Belite Bio's return on equity. Company Net Margins Return on Equity Return on Assets Perrigo -41.85% 11.25% 4.08% Belite Bio N/A -11.84% -11.62%

Does the media prefer PRGO or BLTE?

In the previous week, Perrigo had 2 more articles in the media than Belite Bio. MarketBeat recorded 5 mentions for Perrigo and 3 mentions for Belite Bio. Perrigo's average media sentiment score of 0.58 beat Belite Bio's score of -0.09 indicating that Perrigo is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perrigo 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Belite Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor PRGO or MANE?

In the previous week, Veradermics had 4 more articles in the media than Perrigo. MarketBeat recorded 9 mentions for Veradermics and 5 mentions for Perrigo. Perrigo's average media sentiment score of 0.58 beat Veradermics' score of 0.44 indicating that Perrigo is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perrigo 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Veradermics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer EWTX or PRGO?

In the previous week, Edgewise Therapeutics had 2 more articles in the media than Perrigo. MarketBeat recorded 7 mentions for Edgewise Therapeutics and 5 mentions for Perrigo. Edgewise Therapeutics' average media sentiment score of 1.16 beat Perrigo's score of 0.58 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Perrigo 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Perrigo (PRGO) Competitors

$14.22 +0.52 (+3.80%)

As of 08/21/2026 03:58 PM Eastern

Compare

PRGO vs. LNTH, BLTE, AMRX, MANE, and EWTX

Should you buy Perrigo stock or one of its competitors? Perrigo's main competitors and comparable companies include Lantheus (LNTH), Belite Bio (BLTE), Amneal Pharmaceuticals (AMRX), Veradermics (MANE), and Edgewise Therapeutics (EWTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Perrigo compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Perrigo (NYSE:PRGO) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

Lantheus has a net margin of 17.69% compared to Perrigo's net margin of -41.85%. Lantheus' return on equity of 28.10% beat Perrigo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.69%	28.10%	14.35%
Perrigo	-41.85%	11.25%	4.08%

Lantheus presently has a consensus target price of $108.11, suggesting a potential upside of 8.14%. Perrigo has a consensus target price of $19.33, suggesting a potential upside of 35.96%. Given Perrigo's higher probable upside, analysts plainly believe Perrigo is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

99.1% of Lantheus shares are held by institutional investors. Comparatively, 95.9% of Perrigo shares are held by institutional investors. 1.7% of Lantheus shares are held by insiders. Comparatively, 0.4% of Perrigo shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Lantheus has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.56B	4.19	$233.56M	$4.14	24.15
Perrigo	$4.25B	0.46	-$1.43B	-$12.51	N/A

In the previous week, Lantheus had 6 more articles in the media than Perrigo. MarketBeat recorded 11 mentions for Lantheus and 5 mentions for Perrigo. Lantheus' average media sentiment score of 1.26 beat Perrigo's score of 0.58 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Perrigo	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Lantheus has a beta of -0.03, meaning that its stock price is 103% less volatile than the broader market. Comparatively, Perrigo has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

Summary

Lantheus beats Perrigo on 13 of the 16 factors compared between the two stocks.

How does Perrigo compare to Belite Bio?

Perrigo (NYSE:PRGO) and Belite Bio (NASDAQ:BLTE) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

Belite Bio has a net margin of 0.00% compared to Perrigo's net margin of -41.85%. Perrigo's return on equity of 11.25% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-41.85%	11.25%	4.08%
Belite Bio	N/A	-11.84%	-11.62%

In the previous week, Perrigo had 2 more articles in the media than Belite Bio. MarketBeat recorded 5 mentions for Perrigo and 3 mentions for Belite Bio. Perrigo's average media sentiment score of 0.58 beat Belite Bio's score of -0.09 indicating that Perrigo is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perrigo	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Belite Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Belite Bio has lower revenue, but higher earnings than Perrigo. Belite Bio is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.25B	0.46	-$1.43B	-$12.51	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

Perrigo has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.22, meaning that its share price is 222% less volatile than the broader market.

95.9% of Perrigo shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 0.4% of Perrigo shares are held by company insiders. Comparatively, 13.3% of Belite Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Perrigo currently has a consensus target price of $19.33, indicating a potential upside of 35.96%. Belite Bio has a consensus target price of $205.80, indicating a potential upside of 27.78%. Given Perrigo's higher probable upside, analysts plainly believe Perrigo is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Perrigo beats Belite Bio on 9 of the 15 factors compared between the two stocks.

How does Perrigo compare to Amneal Pharmaceuticals?

Perrigo (NYSE:PRGO) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

In the previous week, Perrigo had 5 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 5 mentions for Perrigo and 0 mentions for Amneal Pharmaceuticals. Perrigo's average media sentiment score of 0.58 beat Amneal Pharmaceuticals' score of 0.37 indicating that Perrigo is being referred to more favorably in the media.

Company	Overall Sentiment
Perrigo	Positive
Amneal Pharmaceuticals	Neutral

Perrigo has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market.

Amneal Pharmaceuticals has a net margin of 5.05% compared to Perrigo's net margin of -41.85%. Perrigo's return on equity of 11.25% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-41.85%	11.25%	4.08%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

Amneal Pharmaceuticals has lower revenue, but higher earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.25B	0.46	-$1.43B	-$12.51	N/A
Amneal Pharmaceuticals	$3.02B	1.89	$72.06M	$0.49	36.55

95.9% of Perrigo shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 0.4% of Perrigo shares are held by company insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Perrigo currently has a consensus target price of $19.33, indicating a potential upside of 35.96%. Amneal Pharmaceuticals has a consensus target price of $17.67, indicating a potential downside of 1.36%. Given Perrigo's higher probable upside, research analysts clearly believe Perrigo is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Amneal Pharmaceuticals beats Perrigo on 11 of the 17 factors compared between the two stocks.

How does Perrigo compare to Veradermics?

Perrigo (NYSE:PRGO) and Veradermics (NYSE:MANE) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Veradermics has lower revenue, but higher earnings than Perrigo. Veradermics is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.25B	0.46	-$1.43B	-$12.51	N/A
Veradermics	N/A	N/A	-$70M	-$1.90	N/A

95.9% of Perrigo shares are held by institutional investors. 0.4% of Perrigo shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Veradermics had 4 more articles in the media than Perrigo. MarketBeat recorded 9 mentions for Veradermics and 5 mentions for Perrigo. Perrigo's average media sentiment score of 0.58 beat Veradermics' score of 0.44 indicating that Perrigo is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perrigo	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Veradermics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Veradermics has a net margin of 0.00% compared to Perrigo's net margin of -41.85%. Perrigo's return on equity of 11.25% beat Veradermics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-41.85%	11.25%	4.08%
Veradermics	N/A	N/A	N/A

Perrigo currently has a consensus price target of $19.33, suggesting a potential upside of 35.96%. Veradermics has a consensus price target of $153.00, suggesting a potential upside of 48.07%. Given Veradermics' stronger consensus rating and higher possible upside, analysts plainly believe Veradermics is more favorable than Perrigo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Perrigo and Veradermics tied by winning 7 of the 14 factors compared between the two stocks.

How does Perrigo compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Perrigo (NYSE:PRGO) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.

Edgewise Therapeutics has higher earnings, but lower revenue than Perrigo. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
Perrigo	$4.25B	0.46	-$1.43B	-$12.51	N/A

Edgewise Therapeutics has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market. Comparatively, Perrigo has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

In the previous week, Edgewise Therapeutics had 2 more articles in the media than Perrigo. MarketBeat recorded 7 mentions for Edgewise Therapeutics and 5 mentions for Perrigo. Edgewise Therapeutics' average media sentiment score of 1.16 beat Perrigo's score of 0.58 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Perrigo	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Edgewise Therapeutics currently has a consensus target price of $50.33, suggesting a potential upside of 13.93%. Perrigo has a consensus target price of $19.33, suggesting a potential upside of 35.96%. Given Perrigo's higher possible upside, analysts plainly believe Perrigo is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Edgewise Therapeutics has a net margin of 0.00% compared to Perrigo's net margin of -41.85%. Perrigo's return on equity of 11.25% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
Perrigo	-41.85%	11.25%	4.08%

95.9% of Perrigo shares are held by institutional investors. 21.3% of Edgewise Therapeutics shares are held by company insiders. Comparatively, 0.4% of Perrigo shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Edgewise Therapeutics beats Perrigo on 9 of the 16 factors compared between the two stocks.

Get Perrigo News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRGO vs. The Competition

Export

Metric	Perrigo	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$1.98B	$12.57B	$7.37B	$24.30B
Dividend Yield	8.14%	2.61%	2.53%	3.70%
P/E Ratio	-1.14	789.80	272.60	30.31
Price / Sales	0.46	764.53	618.96	19.91
Price / Cash	2.69	96.77	78.62	32.49
Price / Book	0.78	11.89	13.05	6.77
Net Income	-$1.43B	$2.81B	$3.47B	$1.07B
7 Day Performance	9.16%	1.77%	2.09%	-0.65%
1 Month Performance	40.74%	3.85%	6.64%	3.38%
1 Year Performance	-41.94%	6.56%	25.02%	14.90%

Perrigo Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRGO Perrigo	3.7712 of 5 stars	$14.22 +3.8%	$19.33 +36.0%	-41.9%	$1.98B	$4.25B	N/A	8,100
LNTH Lantheus	3.5534 of 5 stars	$100.98 +0.0%	$108.11 +7.1%	+71.7%	$6.59B	$1.54B	24.39	1,193	Positive News
BLTE Belite Bio	3.3505 of 5 stars	$167.26 +2.6%	$203.00 +21.4%	+150.1%	$6.54B	N/A	N/A	10	Analyst Downgrade
AMRX Amneal Pharmaceuticals	2.8731 of 5 stars	$17.88 -1.4%	$17.67 -1.2%	+86.8%	$5.79B	$3.02B	36.49	8,500	Positive News
MANE Veradermics	2.2378 of 5 stars	$110.72 -3.2%	$153.00 +38.2%	N/A	$4.78B	N/A	N/A	19	News Coverage Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:PRGO) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Perrigo (PRGO) Competitors